Page
%P
-
Article
Open AccessClinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis
Osimertinib—the third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI)—has been widely used as a first-line treatment for patients with metastatic EGFR-mutant non-small cell lung...